StockData

Agenus vs Monte Rosa Therapeutics

AGEN and GLUE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGEN and GLUE compare

Monte Rosa Therapeutics is the larger company, worth 2.7 times as much as Agenus ($774M against $283M).

Agenus grew revenue faster over the last twelve months (30.5% versus −83.9% for Monte Rosa Therapeutics).

Monte Rosa Therapeutics scores higher on the StockData Score (7 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGENGLUE
Size and price
Market cap$283M$774M
Share price$6.29$9.07
Change, 1 year45.3%−36.8%
Change, 5 years−90.3%−55.9%
Beta (5Y)1.012.02
Employees81150
StockData Score
Total score37 (better)
Valuation score11
Growth score2 (better)0
Performance score01 (better)
Health score05 (better)
Dividend score00
Valuation
P/S2.1× (better)26.9×
P/B–1.6×
EV/EBITDA7.0×–
FCF yield−34.8%−4.1% (better)
Fair value–$6.54
Margin of safety–−38.7%
Growth
Revenue growth (TTM)30.5% (better)−83.9%
Revenue growth, 5Y average5.3%–
Net income growth (TTM)–−767%
EPS growth (TTM)–−707%
Profitability
Gross margin99.5%–
Operating margin27.3% (better)−633%
Net margin–−561%
FCF margin−74.2% (better)−112%
Return on equity–−42.7%
Financial health
Debt / equity–0.00
Net debt / EBITDA0.28–
Interest coverage0.6×–
Current ratio0.3410.58 (better)
Altman Z-score−16.541.30 (better)
Piotroski F-score–5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions31.7%109%
Held by insiders6.6%11.5%
Insider net buying, 12 months–−$4.1M
Superinvestors holding–1
Short interest, % of float18.1%27.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.